ABBISKO CAYMAN DL-00001 - Asset Resilience Ratio
ABBISKO CAYMAN DL-00001 (8ZD) has an Asset Resilience Ratio of 57.39% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ABBISKO CAYMAN DL-00001 (8ZD) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how ABBISKO CAYMAN DL-00001's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of ABBISKO CAYMAN DL-00001.
Liquid Assets Composition Over Time
This chart breaks down ABBISKO CAYMAN DL-00001's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read ABBISKO CAYMAN DL-00001 (8ZD) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.35 Billion | 57.39% |
| Total Liquid Assets | €1.35 Billion | 57.39% |
Asset Resilience Insights
- Very High Liquidity: ABBISKO CAYMAN DL-00001 maintains exceptional liquid asset reserves at 57.39% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ABBISKO CAYMAN DL-00001 Industry Peers by Asset Resilience Ratio
Compare ABBISKO CAYMAN DL-00001's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for ABBISKO CAYMAN DL-00001 (2022–2025)
The table below shows the annual Asset Resilience Ratio data for ABBISKO CAYMAN DL-00001.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.39% | €1.35 Billion ≈ $1.58 Billion |
€2.35 Billion ≈ $2.75 Billion |
-21.86pp |
| 2024-12-31 | 79.25% | €1.67 Billion ≈ $1.95 Billion |
€2.11 Billion ≈ $2.46 Billion |
+13.69pp |
| 2023-12-31 | 65.56% | €1.39 Billion ≈ $1.62 Billion |
€2.12 Billion ≈ $2.47 Billion |
-3.16pp |
| 2022-12-31 | 68.72% | €1.71 Billion ≈ $2.00 Billion |
€2.49 Billion ≈ $2.91 Billion |
-- |
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus … Read more